294 related articles for article (PubMed ID: 34228476)
1. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB
Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476
[TBL] [Abstract][Full Text] [Related]
2. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
3. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Sohn M; Dietrich JW; Nauck MA; Lim S
Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
[TBL] [Abstract][Full Text] [Related]
4. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
5. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
8. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
Marfella R; Prattichizzo F; Sardu C; Rambaldi PF; Fumagalli C; Marfella LV; La Grotta R; Frigé C; Pellegrini V; D'Andrea D; Cesaro A; Calabrò P; Pizzi C; Antonicelli R; Ceriello A; Mauro C; Paolisso G
Cardiovasc Diabetol; 2024 Jan; 23(1):10. PubMed ID: 38184582
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
[TBL] [Abstract][Full Text] [Related]
14. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
15. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
Gómez-Huelgas R; Sanz-Cánovas J; Cobos-Palacios L; López-Sampalo A; Pérez-Belmonte LM
Eur J Intern Med; 2022 Feb; 96():26-33. PubMed ID: 34799233
[TBL] [Abstract][Full Text] [Related]
17. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
Berkovic MC; Bilic-Curcic I; Bozek T; Mahecic DH; Majanovic SK; Canecki-Varzic S; Andric J; Marusic S; Mrzljak A
World J Diabetes; 2020 Nov; 11(11):540-552. PubMed ID: 33269065
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.
Nørgaard CH; Starkopf L; Gerds TA; Vestergaard P; Bonde AN; Fosbøl E; Køber L; Wong ND; Torp-Pedersen C; Lee CJ
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):549-556. PubMed ID: 34215881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]